Spark Therapeutics (ONCE) Given a $66.00 Price Target by Raymond James Financial Analysts

Raymond James Financial set a $66.00 price objective on Spark Therapeutics (NASDAQ:ONCE) in a report issued on Wednesday. The brokerage currently has a buy rating on the biotechnology company’s stock.

Other research analysts have also issued reports about the stock. SunTrust Banks upped their price objective on shares of Spark Therapeutics to $113.00 and gave the stock a buy rating in a report on Thursday. Cantor Fitzgerald set a $105.00 price objective on shares of Spark Therapeutics and gave the stock a buy rating in a report on Wednesday. BMO Capital Markets set a $67.00 price objective on shares of Spark Therapeutics and gave the stock a buy rating in a report on Tuesday. Goldman Sachs Group lowered shares of Spark Therapeutics from a buy rating to a neutral rating and decreased their price objective for the stock from $106.00 to $58.00 in a report on Thursday, December 14th. They noted that the move was a valuation call. Finally, Barclays restated a buy rating and issued a $54.00 price objective on shares of Spark Therapeutics in a report on Wednesday, December 13th. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating and fifteen have assigned a buy rating to the company. The company currently has a consensus rating of Buy and an average target price of $76.03.

Shares of Spark Therapeutics (NASDAQ:ONCE) traded down $3.92 on Wednesday, reaching $51.84. 1,790,000 shares of the company’s stock traded hands, compared to its average volume of 1,420,000. The stock has a market cap of $1,920.00 and a PE ratio of -7.20. Spark Therapeutics has a fifty-two week low of $41.06 and a fifty-two week high of $91.75.

Spark Therapeutics (NASDAQ:ONCE) last announced its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($1.90) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.79) by ($0.11). The firm had revenue of $1.90 million for the quarter, compared to analysts’ expectations of $1.40 million. Spark Therapeutics had a negative net margin of 1,090.11% and a negative return on equity of 60.01%. The company’s quarterly revenue was up 45.8% on a year-over-year basis. During the same period in the previous year, the company earned ($1.07) EPS. analysts expect that Spark Therapeutics will post -7.58 EPS for the current year.

In related news, insider Daniel Faga sold 6,000 shares of the stock in a transaction dated Friday, October 20th. The shares were sold at an average price of $79.95, for a total value of $479,700.00. Following the completion of the transaction, the insider now directly owns 6,000 shares in the company, valued at approximately $479,700. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Barge Joseph La sold 5,500 shares of the stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $71.44, for a total transaction of $392,920.00. Following the completion of the transaction, the insider now owns 8,146 shares of the company’s stock, valued at $581,950.24. The disclosure for this sale can be found here. Over the last quarter, insiders sold 62,309 shares of company stock valued at $4,621,085. 7.30% of the stock is owned by company insiders.

Several institutional investors have recently modified their holdings of the stock. Ameritas Investment Partners Inc. increased its stake in Spark Therapeutics by 23.6% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,040 shares of the biotechnology company’s stock valued at $122,000 after purchasing an additional 389 shares in the last quarter. Cubist Systematic Strategies LLC bought a new stake in Spark Therapeutics during the 2nd quarter valued at about $143,000. BNP Paribas Arbitrage SA increased its stake in Spark Therapeutics by 530.1% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 2,911 shares of the biotechnology company’s stock valued at $174,000 after purchasing an additional 2,449 shares in the last quarter. Pacad Investment Ltd. increased its stake in Spark Therapeutics by 75.0% during the 2nd quarter. Pacad Investment Ltd. now owns 3,500 shares of the biotechnology company’s stock valued at $209,000 after purchasing an additional 1,500 shares in the last quarter. Finally, Teacher Retirement System of Texas bought a new stake in Spark Therapeutics during the 3rd quarter valued at about $225,000. Institutional investors own 94.91% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This news story was posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this news story on another domain, it was illegally copied and reposted in violation of US & international trademark and copyright law. The legal version of this news story can be accessed at https://www.chaffeybreeze.com/2018/01/04/spark-therapeutics-once-given-a-66-00-price-target-by-raymond-james-financial-analysts.html.

About Spark Therapeutics

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Analyst Recommendations for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply